XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
 9 Months Ended
Sep. 30, 2023
Deferred Royalty Obligation [Abstract]  
Schedule of Royalty Obligation transaction

The following table shows the activity of the deferred royalty obligation since transaction inception through September 30, 2023:

 

 

 

September 30,

 

 

 

2023

 

 

 

(in thousands)

 

Proceeds from the sale of future Vaxcyte royalties

 

$

140,000

 

Issuance costs

 

 

(3,792

)

Non-cash interest expense associated with the sale of future Vaxcyte royalties

 

 

6,378

 

Amortization of issuance costs

 

 

177

 

Deferred royalty obligation related to the sale of future Vaxcyte royalties, net

 

$

142,763